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Abstract. 
 
Three hallmark features of the cardiac hy-
pertrophic growth program are increases in cell size, 
sarcomeric organization, and the induction of certain 
cardiac-specific genes. All three features of hypertro-
phy are induced in cultured myocardial cells by 
 
a
 
1
 
-
adrenergic receptor agonists, such as phenylephrine 
(PE) and other growth factors that activate mitogen-
activated protein kinases (MAPKs). In this study the 
MAPK family members extracellular signal–regulated 
kinase (ERK), c-jun NH
 
2
 
-terminal kinase (JNK), and 
p38 were activated by transfecting cultured cardiac my-
ocytes with constructs encoding the appropriate kinases 
possessing gain-of-function mutations. Transfected 
cells were then analyzed for changes in cell size, sarco-
meric organization, and induction of the genes for the 
A- and B-type natriuretic peptides (NPs), as well as the 
 
a
 
-skeletal actin (
 
a
 
-SkA) gene. While activation of JNK 
and/or ERK with MEKK1
 
COOH
 
 or Raf-1 BXB, respec-
tively, augmented cell size and effected relatively 
modest increases in NP and 
 
a
 
-SkA promoter activities, 
neither upstream kinase conferred sarcomeric organi-
zation. However, transfection with MKK6 (Glu), which 
specifically activated p38, augmented cell size, induced 
NP and 
 
a
 
-Ska promoter activities by up to 130-fold, and 
elicited sarcomeric organization in a manner similar to 
PE. Moreover, all three growth features induced by 
MKK6 (Glu) or PE were blocked with the p38-specific 
inhibitor, SB 203580. These results demonstrate novel 
and potentially central roles for MKK6 and p38 in the 
regulation of myocardial cell hypertrophy.
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1. 
 
Abbreviations used in this paper
 
: 
 
a
 
-SkA, 
 
a
 
-skeletal actin; ANP and
BNP, A- and B-type cardiac natriuretic peptides; ATF, activating tran-
scription factor; CMV, cytomegalovirus; ERK, extracellular signal–regu-
lated kinase; HA, hemagglutinin; hsp, heat-shock protein; JNK, NH
 
2
 
-ter-
minal kinase; MAPK, mitogen-activated protein kinase; MAPKAP,
MAPK-activated protein kinase; PE, phenylephrine.
 
C
 
ardiac 
 
myocytes, which are postmitotic, increase
in size during postnatal development through a
well-studied hypertrophic growth program. Myo-
cardial cell hypertrophic growth is characterized by a num-
ber of phenotypic changes, including the activation of sev-
eral immediate early genes (e.g., c-fos, c-jun, and egr-1),
increased expression of genes encoding certain sarcomeric
proteins (e.g., 
 
a
 
-skeletal actin, 
 
b
 
-myosin heavy chain, and
myosin light chain-2), and the induction of the genes for
the A- and B-type cardiac natriuretic peptides (ANP and
BNP)
 
1
 
 (Schneider et al., 1992; Van Bilsen and Chien, 1993;
Lembo et al., 1995). Although myocardial mass in the fully
developed adult does not generally undergo significant in-
creases in size, in some pathological conditions, such as
overload-induced hypertrophy, adult cardiac myocytes do
reenter a hypertrophic growth program very similar to
that observed in the developing neonatal heart (Schneider
et al., 1992; Van Bilsen and Chien, 1993; Lembo et al.,
1995; Van Heugten et al., 1995; Yamazaki et al., 1995).
Cultured neonatal rat ventricular cardiac myocytes have
served as a model system for studies aimed at gaining a
better understanding of this interesting mechanism of cell
growth. Primary myocardial cells respond to a variety of
stimuli by undergoing a hypertrophic growth program vir-
tually identical to that observed in the developing neonate
and the pathologic adult myocardium (Van Bilsen and
Chien, 1993). For example, cultured myocardial cells treated
with the 
 
a
 
1
 
-adrenergic receptor agonist, phenylephrine
(PE), various other growth factors, or mechanical loading
or electrical pacing of contractions display marked in-
creases in size, enhanced sarcomeric organization, and in-
duction of the cardiac genes associated with the hyper-
trophic growth program (Simpson, 1983; Komuro et al.,
1990; McDonough and Glembotski, 1992; LaMorte et al.,
1994; Sadoshima et al., 1995; Bogoyevitch et al., 1995
 
b
 
;
Karns et al., 1995; Sprenkle et al., 1995; LaPointe et al.,
1996; Thuerauf and Glembotski, 1997). The convergence
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of these diverse stimuli on the features that define myocar-
dial cell growth suggests that a select group of intracellular
signaling pathways are coordinately activated by these
treatments. Accordingly, a better understanding of myo-
cardial cell signaling pathways that contribute to hyper-
trophic growth is required to fully grasp normal cardiac
development as well as counterproductive pathological
growth.
Studies of the intracellular signaling mechanisms respon-
sible for myocardial cell growth have focused on the mito-
gen-activated protein kinases (MAPK), in part because at
least one of the MAPKs, extracellular signal–regulated ki-
nase (ERK), has been implicated in mitogenic growth in a
variety of cell types (Cobb et al., 1991). Typically, ERK is
activated via the well-known sequential pathway some-
times referred to as a MAPK module. MAPK modules
consist of three members, a MAPKKK, followed by a
MAPKK and then the terminal MAPK, itself. In the case
of the ERK pathway, Ras stimulates the MAPKKK, Raf-1,
which activates the MAPKK known as MEK (Kyriakis et
al., 1992; Davis, 1993).
In cultured cardiac myocytes, PE activates Ras, Raf, MEK,
and ERK (Thorburn and Thorburn, 1994; Bogoyevitch et
al., 1993
 
a
 
, 
 
b
 
 Clerk et al., 1994; Thorburn et al., 1994
 
a
 
), and
transfection of constructs encoding active Ras, Raf, or
MEK can induce ANP, 
 
b
 
-MHC, 
 
a
 
-skeletal actin (
 
a
 
-SkA)
and/or MLC-2 promoter activities (Thorburn et al., 1993,
1994
 
b
 
; Abdellatif et al., 1994; Thuerauf and Glembotski,
1997) . Moreover, dominant interfering forms of Ras or Raf
can inhibit PE-induced ERK and cardiac gene promoter
activity (Thorburn et al., 1993, 1994
 
b
 
; Thorburn, 1994),
consistent with a role for ERK in the cardiac growth pro-
gram. However, the overexpression of active forms of ei-
ther Ras or ERK does not lead to the sarcomeric organiza-
tion typical of hypertrophic growth (Thorburn et al.,
1994
 
a
 
,
 
b
 
), and inhibiting MEK with PD 098059 does not
block PE-induced sarcomeric organization or ANP gene
expression (Post et al., 1996). Additionally, while myocar-
dial cell ERK can be activated by some agonists, such as
PE, ET, or FGF, each of which can cause hypertrophic
growth, it can also be activated by agonists, such as ATP or
carbachol, neither of which support myocardial cell growth
(Post et al., 1996). These findings suggest that the activa-
tion of ERK alone is not sufficient to confer hypertrophic
growth and the related gene expression.
Another member of the MAPK family, the stress-kinase
c-Jun NH
 
2
 
-terminal kinase (JNK) (Davis, 1994; Cano and
Mahadevan, 1995; Karin, 1995) has received some atten-
tion as a potential mediator of growth in cardiac myocytes.
The activation cascade for JNK is somewhat less under-
stood than that for ERK. However, it is believed that in
most cells the sequential stimulation of the Ras-like mono-
meric GTP-binding protein, Rac, perhaps by Ras itself,
leads to the activation of MEKK1, a MAPKKK that then
activates the MAPKK, MEK4, also called SEK or JNK ki-
nase, culminating in the activation of c-jun kinase (JNK)/
MAPK (Lange-Carter et al., 1993; Derijard et al., 1994).
JNK is activated in cultured myocardial cells by the
growth promoters PE and ET-1 (Bogoyevitch et al.,
1995
 
a
 
), suggesting that it may contribute to the hyper-
trophic phenotype. Transfection of cultured myocardial
cells with a construct encoding active MEKK1 leads to an
approximately twofold increase in myocardial cell size and
5–50-fold enhancement of ANP, 
 
b
 
-MHC, and 
 
a
 
-SkA pro-
moter activities (Bogoyevitch et al., 1995
 
a
 
, 1996). However,
there have been no reports that JNK activation fosters the
sarcomeric organization that is an obligate feature of the
hypertrophic phenotype. Thus, it appears that like the
ERK pathway, the JNK pathway alone may not be suffi-
cient to support all of the main features associated with
the hypertrophic growth program.
The third and most recently characterized member of
the MAPK family is the stress-kinase, p38, also known as
protein kinase HOG1 (Rouse et al., 1994; Raingeaud et
al., 1995). In comparison to the JNK pathway but in con-
trast to ERK, the p38 pathway is not commonly activated
by mitogens but is induced by cell stresses such as endo-
toxins, osmotic shock, or metabolic inhibitors. The up-
stream activators of p38 are poorly understood; however,
recent studies have resulted in the cloning and character-
ization of members of the p38 MAPKK module, most no-
tably MKK4, which can activate both JNK and p38 (Lin et
al., 1995), and MKK3 (Derijard et al., 1995) and MKK6
(Raingeaud et al., 1996; Han et al., 1996), either of which
specifically activate p38. MKK6 is also known as SAPKK3
(Cuenda et al., 1996).
In previous studies, it was shown that a p38-like kinase is
induced in isolated perfused rat heart after precondition-
ing, which is a brief ischemic treatment known to protect
cardiac tissue from damage due to subsequent ischemic
episodes taking place soon thereafter (Bogoyevitch et al.,
1996; Maulik et al., 1996). The possibility that p38 activa-
tion could contribute to the protective effects of precondi-
tioning is consistent with findings that p38 can lead to the
phosphorylation of heat-shock proteins (Stokoe et al.,
1992
 
b
 
), a modification thought to enhance their cell-pro-
tective effects. However, the putative role of the p38 path-
way in the hypertrophic growth of cardiac myocytes has
not been assessed.
The goal of the present study was to compare the effects
of activating the p38 pathway with activation of ERK and
JNK on the three major features of the myocardial cell hy-
pertrophic growth program- cell size, sarcomeric organiza-
tion, and activation of cardiac gene expression. It was
found that only p38 activation conferred all three features
of myocardial cell growth in a manner similar to that ob-
served using PE. These results suggest that p38 plays a
central role in mediating the cardiac hypertrophic growth
pathway, a concept that could also be applicable to other
terminally differentiated cell types.
 
Materials and Methods
 
Cell Culture
 
Primary ventricular myocytes were prepared from 1–4-d-old neonatal rats
as previously described (Sprenkle et al., 1995; Thuerauf and Glembotski,
1997). After the enzymatic dissociation of ventricular tissue, the cells were
plated onto uncoated plastic dishes in DME/F-12 (1:1)/10% FBS for 1 h
during which time most of the fibroblasts adhered to the dish. The recov-
ered cells were then transfected (see below), plated on fibronectin-coated
plastic dishes or glass slides (3 
 
3
 
 10
 
5
 
 cells/mm
 
2
 
), and then maintained for
about 18 h in DME/F-12 (1:1)/10% FBS. The cultures were then washed
briefly with medium, refed with serum-free DME/F-12 (1:1), maintained
for 48 h, and then either extracted for reporter enzyme assay (see below) 
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or fixed and then analyzed by immunocytofluorescence or staining with
fluorescent phallicidin.
 
Transfections
 
After preplating (see above), myocardial cells were resuspended at a den-
sity of 30 million cells/ml minimal medium (DMEM:F12 [GIBCO BRL,
Gaithersburg, MD] containing 1 
 
m
 
g/ml BSA) and transfections were car-
ried out as described previously (Sprenkle et al., 1995; Thuerauf and
Glembotski, 1997). Briefly, for each transfection, 300 
 
m
 
l, or 9 million cells,
were mixed with 15–30 
 
m
 
g of either ANP-3003GL (Sprenkle et al., 1995),
BNP-2501GL (Thuerauf and Glembotski, 1997), 
 
a
 
-SkA-394GL (MacLel-
lan et al., 1994), or pG5E1bLuc (Raingeaud et al., 1996); 3–9 
 
m
 
g of cy-
tomegalovirus–
 
b
 
-galactosidase (used as a normalization reporter except
where the test construct is known to activate CMV promoter activity
[Gillespie-Brown et al., 1995; Paradis et al., 1996; Post et al., 1996]); and in
some experiments, 15–45 
 
m
 
g of an activated Ras, Rac, Raf-1, JNKKK,
MKK6, activating transcription factor-2 (ATF2)/Gal4, or MEF2C/Gal4
expression construct (see below). The levels of plasmid used in each cul-
ture within an experiment were equalized using empty vector DNA, such
as pCEP. Each 300-
 
m
 
l aliquot was then electroporated in a Bio-Rad (Her-
cules, CA) Gene Pulser at 700 V, 25 
 
m
 
F, 100 
 
V
 
 in a 0.2-cm-gap cuvette, a
protocol that allows for the selective transfection of only cardiac myocytes
(Sprenkle et al., 1995). This procedure results in an 
 
z
 
30% viability
(Sprenkle et al., 1995); Accordingly, the 3 million viable cells were plated
into fibronectin-coated 35-mm wells, at 1 
 
3
 
 10
 
6
 
 cells/well, into 24-mm
wells at 0.5 
 
3
 
 10
 
6
 
 cells/well, or into four-chamber Lab Tek chamber slides
at 0.3 
 
3
 
 10
 
6
 
 cells/2 cm
 
2
 
 well.
 
Reporter Enzyme Assays
 
Transfected cells were maintained in DMEM:F12 supplemented with 10%
FBS for 
 
z
 
16 h after electroporation. The cells were then washed thor-
oughly and the medium was replaced with minimal medium. Unless otherwise
stated, 24 h later, the medium was again replaced with minimal medium
 
6
 
 50 
 
m
 
M phenylephrine with 1 
 
m
 
M propranolol added to block 
 
b
 
-adrener-
gic receptors. Luciferase and 
 
b
 
-galactosidase assays were performed as
described (Sprenkle et al., 1995). Luciferase activity was measured for 30 s
on a Bio Orbit 1251 Luminometer (Pharmacia Biotech. Inc., Piscataway,
NJ). Data are expressed as “Relative Luciferase (Rel Luc)” 
 
5
 
 arbitrary
integrated luciferase units/
 
b
 
-galactosidase units, representative of at least
three independent experiments performed with two different plasmid prepara-
tions, and represent the mean and SEM of triplicate 35- or 24-mm wells.
 
Test Expression Constructs
 
To assess the effects of various signaling proteins, the following constructs
were used: pDCR H-Ras
 
V12
 
 (codes for activated Ha-Ras; from D. Bar-
Sagi, State University of New York at Stony Brook, NY), pDCR Rac
 
V12
 
(codes for activated Rac; from M. Cobb and J. Frost, University of Texas
Southwestern Medical Center, Dallas, TX), RSV-Raf-1 BXB (codes for
activated Raf-1 kinase; from U. Rapp, University of Wurzburg, Wurzburg,
Germany), pCMV5 MEKK
 
COOH
 
 (codes for activated MEKK-1; from G.
Johnson, University of Colorado, Denver, CO), pcDNA3 MKK6 (Glu)
(codes for activated MKK6, or p38/MAPKK; from R. Davis, University of
Massachusetts, Worcester MA), ATF2/Gal4 (codes for the ATF2 tran-
scriptional activation domain fused to the Gal4 DNA–binding domain;
from R. Davis), MEF2C/Gal4 (codes for MEF2C fused to the Gal4 DNA–
binding domain; from J. Han, The Scripps Research Institute, La Jolla,
CA), MEF2C-S/Gal4 (codes for mutant [Ser to Ala 387] MEF2C fused to
the Gal4 DNA–binding domain; from J. Han), pG5E1bLuc (codes for 5X
Gal4 sites cloned upstream of a prolactin promoter driving luciferase ex-
pression; from R. Davis). Preliminary experiments using different concen-
trations of each construct verified that optimal doses were chosen.
 
Immunocytofluorescence: Morphometric Analyses
 
To study the effects of activating the MAPK pathways on cell size and sar-
comeric organization, myocardial cells were cotransfected with a test ex-
pression construct or an empty vector control and CMV–
 
b
 
-galactosidase.
Double-staining experiments demonstrated a cotransfection efficiency of
 
z
 
85%. After treatment for 48 h with or without PE, cultures were fixed,
as described (McDonough and Glembotski, 1992). Transfected cardiac
myocytes were identified by immunostaining for 
 
b
 
-galactosidase using a
Texas red–conjugated anti–mouse IgG. Since the 
 
b
 
-galactosidase is cyto-
solic, staining was uniform throughout the myocardial cells, facilitating the
determination of cell area (see below). The same samples were also
stained with BODIPY-conjugated phallicidin, an actin-specific stain, to
evaluate sarcomeric organization, as described (McDonough and Glem-
botski, 1992).
To study the effects of the test expression constructs on endogenous
cardiac gene expression, myocardial cells were cotransfected with a test
expression construct or an empty vector control and ANP-3003GL. After
fixation, the cells were immunostained for luciferase using a rabbit anti–
luciferase antiserum, and they were immunostained for ANP using a
mouse monoclonal antibody to rat ANP (Glembotski et al., 1987) and vi-
sualized using differential fluorescence. Generally, positive ANP staining
was visualized using a Texas red–conjugated anti–mouse IgG, and positive
luciferase staining was visualized using an FITC-conjugated anti–rabbit IgG.
 
Morphometric Analyses
 
Cell Size. 
 
Transfected myocytes that immunostained positively for 
 
b
 
-galac-
tosidase were microscopically visualized under fluorescent illumination
and photographed. The photographic images were then digitally acquired
using a scanner (model ES-1200C; Epson America, Inc., Torrance, CA)
attached to a Apple Power Mac 8500 (Cupertino, CA). The area in pixels
of each digitized image was determined using NIH Image software and
compared to a standard image possessing an area of 1 
 
m
 
m
 
2
 
. This enabled
the designation of area, in square micrometers, to each cell image; be-
tween 20 and 50 images of different cells derived from each treatment
were analyzed. The values reported are the mean areas, in square mi-
crometers 
 
6
 
 standard error.
 
Sarcomeric Organization.  
 
Transfected myocytes were identified by posi-
tive 
 
b
 
-galactosidase immunostaining and observed using a Texas red–
compatible filter. The cells were then viewed after phalloidin staining
using an FITC-compatible filter and scored positively for sarcomeric orga-
nization if the myofilament alignment resembled that in cells treated with
PE. Approximately 50–100 cells from each of three cultures per treatment
were assessed. Generally, treating CMV–
 
b
 
-galactosidase/pCEP-trans-
fected cells with PE (positive control) or without (negative control) re-
sulted in 
 
z
 
25 and 2% of the 
 
b
 
-galactosidase–positive cells scoring for sar-
comeric organization, respectively. In experimental cultures transfected
with CMV–
 
b
 
-galactosidase and a test construct, the number of cells scor-
ing positive for sarcomeres was normalized to (divided by) the number of
cells scoring positive for sarcomeres obtained with PE, which gave maxi-
mal values, and the results are displayed as percentages of maximal values.
 
MAPK Assays
 
To test the effects of treatments on MAPK activity levels, hemagglutinin
(HA)-tagged forms of ERK1 (pCEP4 HA-wt-ERK1 from M. Cobb), JNK
(SRa-HA-JNK from G. Johnson) or p38 (pCEP4 HA-wt-p38Hog1 from
M. Cobb) were cotransfected with the test constructs. After the appropri-
ate times, cultures were extracted in a buffer containing 10 mM Tris, pH
7.6, 1% Triton X-100, 0.05 M NaCl, 5 mM EDTA, 2 mM 
 
o
 
-vanadate, and
20 
 
m
 
g/ml aprotinin. After brief centrifugation, extracts were incubated for
2 h at 4
 
8
 
C with HA monoclonal antibody (12CA5; Boehringer-Mannheim
Corp., Indiannapolis, IN), bound to protein A–Sepharose (Pharmacia
Biotech, Inc.) and immune-complex kinase assays were carried out using
the appropriate substrates, as described (Derijard et al., 1994; Post et al.,
1996). Briefly, reactions were initiated by the addition of 1 
 
m
 
g of the ap-
propriate substrate, MBP for ERK, GST–c-Jun for JNK, Phas-I for p38,
and 6 
 
m
 
M [
 
g
 
-
 
32
 
P]ATP (5,000 Ci/mmol) in a final volume of 30 
 
m
 
l of kinase
buffer (20 mM Hepes, pH 7.4, 20 mM MgCl
 
2
 
, 20 mM 
 
b
 
-glycerophosphate,
2 mM DTT, 20 
 
m
 
M ATP). After 30 min at 25
 
8
 
C, the reactions were termi-
nated by the addition of Laemmli sample buffer, and the phosphorylation
level of substrate proteins was evaluated by SDS-PAGE followed by auto-
radiography and phosphorimage analyses.
In each experiment, two identically treated cultures (1.5 
 
3
 
 10
 
6
 
 cells/35-
mm dish) were used for each treatment, and after densitometric analyses of
the exposed phosphorimage plates, values for each treatment were averaged.
 
Results
 
MKK6 (Glu) Selectively Activates p38
in Myocardial Cells and Strongly Stimulates
Cardiac Gene Expression
 
To characterize the effects of overexpressing various sig- 
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naling proteins on each of the three MAPK family mem-
bers in the cardiac context, myocardial cells were cotrans-
fected with constructs encoding gain-of-function forms of
Ras, Rac, Raf-1 kinase, JNKK kinase, or p38 kinase, and
constructs encoding HA-tagged p38, JNK, or ERK. In the
cardiac myocytes, Ras V12 served as a poor activator of ei-
ther p38 or JNK, but as expected, it was a strong activator
of ERK (Fig. 1). Rac V12 had no effect on p38 or ERK in
the cardiac cells; however, it strongly activated JNK, con-
sistent with its hypothesized ability to serve as an up-
stream activator of MEKK1 (Lange-Carter et al., 1993;
Derijard et al., 1994). Raf BXB, which encodes an active
form of Raf-1 kinase (Bruder et al., 1992; Kolch et al., 1993),
served primarily as an ERK activator, while MEKK
 
COOH
 
,
a truncated active form of MEKK1 (Lange-Carter et al.,
1993), mildly activated p38 by about fourfold, moderately
activated JNK by 8–10-fold, as expected, but more strongly
stimulated ERK by about 25-fold (Fig. 1). The ability of
MEKK
 
COOH
 
 to activate both JNK and ERK is consistent
with results in other cell types (Minden et al., 1994). Im-
portantly, however, MKK6 (Glu), an activated form of the
p38 kinase, MKK6 (Raingeaud et al., 1996), potently acti-
vated p38 in the cardiac myocytes by about 16-fold, with
no effect on either ERK or JNK (Fig. 1). A kinase-dead
form of MKK6, MKK6 (K82A) (Raingeaud et al., 1996),
did not activate p38 in the cardiac cells (not shown). These
results verify the utility of constructs encoding activated
forms of Raf, MEKK1, and MKK6 as stimulators of the
MAPK pathways, and in particular, they clearly show that
MKK6 serves as a very selective p38 activator in cardiac
myocytes.
The abilities of the various expression constructs to acti-
vate three cardiac genes (ANP, BNP, and 
 
a
 
-SkA) that
serve as hallmarks of the hypertrophic growth program
were tested using ANP-3003GL, BNP-2501GL, or 
 
a
 
-SkA–
394GL. These reporter constructs possess 3,003, 2,501, or
394 bp of the ANP, BNP, or 
 
a
 
-SkA 5
 
9
 
-flanking sequences,
respectively. As expected from previous studies (Thor-
burn et al., 1993; MacLellan et al., 1994; Thuerauf and
Glembotski, 1997), Ras V12 served as a strong activator of
both natriuretic peptide (NP) promoters, fostering up to
50-fold activation of luciferase expression (Fig. 2). The
Rac V12 construct also activated these promoters, but less
strongly than Ras, 
 
z
 
10-fold; this may reflect the differen-
tial efficacies of ERK and JNK as inducers of the cardiac
genes studied. Although Raf BXB and MEKK
 
COOH
 
 stimu-
lated NP and 
 
a
 
-SkA promoter activities by up to 20-fold,
most notable were the effects of the p38-activating con-
struct, MKK6 (Glu), which stimulated up to 130-fold (Fig.
2). These findings suggest that while each of the MAPK
pathways can stimulate cardiac natriuretic peptide and
 
a
 
-SkA gene expression, the p38 pathway as stimulated
with MKK6 (Glu) confers the strongest induction of the
three genes studied.
 
Figure 1.
 
Activation of p38, JNK, and ERK MAP kinases in my-
ocardial cells. Myocardial cells were cotransfected with an ex-
pression construct encoding activated Ras (Ras V12), Rac (Rac
V12), Raf (Raf-1 BXB), JNK kinase (MEKK
 
COOH
 
), p38 kinase
(MKK6 [Glu]), or an empty vector control (pCEP) and either
HA-p38, HA-JNK, or HA-ERK. After a 48-h incubation in se-
rum-free media, the cultures (
 
z
 
3 
 
3
 
 10
 
6
 
 cells each) were extracted
and incubated with an HA monoclonal antibody, and the appro-
priate kinase assay was carried out on the resulting immune com-
plex, as described in the Materials and Methods. After exposing
the resulting SDS gel to a phosphorimager plate, each phosphor-
ylated substrate band was digitized and printed (see the 
 
inset
 
 of
each panel). The relative density of each band was determined
using Molecular Dynamics Image Quant software (Sunnyvale,
CA). Each treatment was carried out on two identical cultures,
and the average of the band density for each treatment was then
normalized to the maximal value obtained in each experiment.
Shown is the percentage of the maximum; the average variation
between duplicate samples was 10% or less. This is representa-
tive of three identical experiments that produced similar results. 
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MKK6 (Glu) Increases Cardiac Myocyte Size and 
Sarcomeric Organization
 
Further studies were undertaken to compare the effects of
Raf BXB, MEKK
 
COOH
 
, and MKK6 (Glu) with the gold
standard, PE, on other features of the program, such as
cell size and sarcomeric organization. Compared to cells
maintained in control media (Fig. 3, 
 
A
 
 
 
and 
 
A
 
9), the PE-
treated cells were much larger (Fig. 3 B), displaying an ap-
proximately two- to three-fold increase in area (Fig. 4 A),
and they possessed a high degree of sarcomeric organiza-
tion (Fig. 3 B9). In general, the PE-treated cultures pos-
sessed about 10-fold more myocytes displaying organized
sarcomeres than the control cultures (Fig. 4 B). PE-treated
cultures also displayed significantly increased levels of en-
dogenous ANP expression, observed as the prototypical
perinuclear staining found often in hypertrophic cardiac
myocytes (Fig. 3, F [control] vs. G [PE-treated]). Interest-
ingly, cultures transfected with Raf BXB or MEKKCOOH
displayed increases in size (Figs. 3, C [BXB] and D
[MEKKCOOH], and 4 A), and while the usual shape of the
Raf BXB–treated cells was similar to PE-treated cells, the
MEKKCOOH-treated cells were almost always very long
and thin. Moreover, while either Raf BXB (Fig. 3 H
[BXB]) or MEKKCOOH (Fig. 3 I [MEKK-1]) fostered the
induction of endogenous ANP expression, neither con-
struct supported sarcomeric organization (Fig. 3 C9 [BXB]
and 3 D9 [MEKK-1]; also see Fig. 4 B). These results sug-
gested that neither ERK (Raf BXB) alone nor ERK and
JNK (MEKKCOOH) were sufficient to confer all the fea-
tures of the hypertrophic phenotype.
When myocardial cells were transfected with MKK6
(Glu), they were on average four times larger than control
cells (Figs. 3, E and 4 A), and notably, they displayed sar-
comeric organization that was visually similar to that ob-
served upon PE treatment (Figs. 3 E9 and 4 B). Consistent
with the high degree of sarcomeric ordering was the find-
ing that cells transfected with MKK6 (Glu) displayed
spontaneous contractile activity. Moreover, like PE-
treated cells, MKK6 (Glu)–transfected myocardial cells
possessed significantly elevated levels of endogenous ANP
(Fig. 3 J), consistent with the ability of MKK6 (Glu) to
strongly activate NP promoter activities (Fig. 2). Thus, it
was apparent that MKK6 (Glu), a selective p38 activator
in the cardiac myocytes, was able to mimic the three hall-
mark features of the hypertrophic growth program.
The Effects of PE and MKK6 Are Sensitive
to a p38 Inhibitor
To demonstrate that the effects of MKK6 (Glu) and PE on
myocardial cell growth and gene expression involved p38,
cultures were treated with the highly specific p38 inhibitor,
Figure 2. Effects of Ras, Rac, and MAP kinase pathway expres-
sion constructs on cardiac-specific promoter activities in myocar-
dial cells. Myocardial cells were cotransfected with an expression
construct encoding activated Ras (Ras V12), Rac (Rac V12), Raf
(Raf-1 BXB), JNKK kinase (MEKKCOOH), p38 kinase (MKK6
[Glu]), or an empty vector control (pCEP) and either an ANP
(ANP-3003GL), BNP (BNP-2501GL), or a-SkA (a-SkA-394GL)
promoter/luciferase reporter construct. These reporter constructs
contain either the full-length, 3,003 bp of rat ANP 59-flanking se-
quence, the full-length, 2,501 bp of rat BNP 59-flanking sequence,
or 2394 bp of the rat a-SkA 59-flanking sequence driving the ex-
pression of a luciferase reporter. All cultures were also trans-
fected with CMV-b-galactosidase. After a 48-h incubation in se-
rum-free media, the cultures were extracted, and luciferase and
b-galactosidase enzyme activities were assessed, as described in
the Materials and Methods. Values for luciferase enzyme units
obtained with each treatment were normalized to the maxima.
Values are means 6 SE, n 5 3 cultures. In this experiment, lu-
ciferase values were not normalized to b-galactosidase since one
of the constructs, MEKKCOOH, is a strong inducer of CMV-driven
reporter expression, and it is believed that such normalization
can be misleading, as previously reported (Gillespie-Brown et al.,
1995; Paradis et al., 1996; Post et al., 1996).The Journal of Cell Biology, Volume 139, 1997 120
Figure 3. Fluorescent microscopic analyses of the effects of Raf-1 BXB, MEKKCOOH, or MKK6 (Glu) expression constructs on size, sar-
comeric organization, and endogenous cardiac-specific gene expression in myocardial cells. Myocardial cells were cotransfected with Raf
(Raf-1 BXB), JNKK kinase (MEKKCOOH), p38 kinase (MKK6 [Glu]), or an empty vector control (pCEP) and CMV–b-galactosidase
(A–E9) or ANP-3003GL (F–J), as described in the legend for Fig. 1. After 48 h of incubation in either serum-free control media or in the
same media containing 10 mM of the a1-adrenergic receptor agonist, phenylephrine (PE) 1 1 mM propranolol (the latter to block poten-
tial binding to b-adrenergic receptors), cultures were fixed in paraformaldehyde. (A–E) b-galactosidase expression (Gal), used to iden-
tify transfected cells, was visualized with a Texas red–conjugated second antibody and photographed using a rhodamine-compatible filter.
(A9–E9) Actin organization in the same b-galactosidase–positive cells shown in A–E was assessed by staining them with BODIPY-conju-
gated phalloidin (Phalloidin) and photographing them using an FITC-compatible filter. (F–J) In a separate experiment, luciferase ex-
pression (Luc), used to identify transfected cells, was visualized with an FITC-conjugated second antibody and photographed using an
FITC-compatible filter. The same cells were also assessed for endogenous ANP expression (ANP), viewed with a Texas red–conjugated
second antibody, and photographed with a rhodamine-compatible filter. The digitized photographic images of luciferase- and ANP-positive
cells were overlaid using Adobe Photoshop (San Jose, CA), and the resulting montage was prepared in Claris MacDraw Pro. Bar, 50 mM.Zechner et al. p38/MAPK as a Mediator of Myocardial Cell Growth 121
SB 203580 (Young et al., 1993). At 20 mM, SB 203580 has
been shown to block p38/MAPK, while concentrations as
high as 100 mM have been shown to have no effect on 20
other protein kinases tested, including ERK and JNK
(Cuenda et al., 1995). In the present study, SB 203580 (20
mM) blocked PE and MKK6 (Glu)–inducible NP pro-
moter activity by between 40 and 70% (Fig. 5, A and B)
Figure 4. Morphometric analyses of the effects of Raf-1 BXB,
MEKKCOOH, or MKK6 (Glu) expression constructs on size and
sarcomeric organization in myocardial cells. (A) Photographic
images of myocardial cells transfected and treated as described in
the legend to Fig. 3, A–E, were digitized and the areas (mm2) of
z20–50 cells from each treatment were determined using NIH
Image software, as described in the Materials and Methods.
Shown are the mean area values for each treatment 6 SE (n 5 3
cultures. (B) The myofilament structure in myocardial cells trans-
fected and treated as described in the legend to Fig. 3, A9–E9, was
evaluated using BODIPY-phalloidin to stain actin. Upon visually
inspecting 50–100 transfected (i.e., b-galactosidase–positive) cells
per treatment using a fluorescence microscope, cells were scored
for possessing organized sarcomeres (i.e., appearing similar to
cells shown in Fig. 3, B9 or E9). The number of cells transfected
with test construct that scored positive for sarcomeric organiza-
tion was normalized to (divided by) the maximal values for sarco-
meric organization, which were obtained by PE treating cells that
had been transfected with the empty vector control; the results
are shown as a percentage of these maximal values. Generally,
z25% of the cells transfected with the empty vector control and
then treated with PE displayed highly organized sarcomeres.
Shown are the mean area values for each treatment 6 SE (n 5 3
cultures).
Figure 5. Effects of SB 203580 on ANP-, BNP-, or ATF2-depen-
dent luciferase production in myocardial cells. Myocardial cells
were cotransfected with MKK6 (Glu) or an empty vector control
(pCEP and pCEP 1 PE) and either ANP-3003GL, BNP-2501GL,
or pG5E1bLuc reporter constructs. In C, cells were also trans-
fected with ATF2/GAL4 (codes for the ATF2 transcriptional ac-
tivation domain fused to the Gal4 DNA–binding domain). All
cells were also transfected with CMV–b-galactosidase for nor-
malization purposes. Cultures were then maintained for 48 h with
or without SB 203580 (20 mM) or with or without DMSO (vehicle
control) and with or without PE (10 mM) 1 propranolol (1 mM),
as shown and then extracted and assayed for luciferase and b-galac-
tosidase reporter activities, as described in Materials and Meth-
ods. Luciferase enzyme units were normalized to b-galactosidase,
and the values obtained with each treatment were normalized to
pCEP 1 PE. Values are means 6 SE, n 5 3 cultures.The Journal of Cell Biology, Volume 139, 1997 122
and decreased MKK6 (Glu)–activated a-SkA by .90%
(not shown). Additionally, myocardial cell p38 was shown
to be activated by PE, as was ERK; however, JNK was not
stimulated under these conditions (Fig. 6). Taken to-
gether, these results confirmed a central role for p38 in
MKK6 (Glu) induction of cardiac gene expression and
strongly suggest that the ability of PE to induce NP ex-
pression is at least partly due to the MKK6/p38 pathway.
The stress-activated MAPK pathways, especially p38,
are well–known stimulators of ATF2 (Gupta et al., 1995;
Raingeaud et al., 1996). ATF2 can dimerize with other
ATF family members (e.g., cAMP response element–bind-
ing protein [CREB] or ATF-1), Rb, NF-kB, or c-jun and
enhance transcription through cAMP response elements,
AP-1 sites, or NF-kB sites. Accordingly, the abilities of
MKK6 (Glu) or PE to activate ATF2-dependent tran-
scription in cardiac myocytes were tested. Myocardial cells
were cotransfected with a reporter plasmid possessing
GAL4 DNA–binding sites cloned upstream of luciferase, a
construct encoding a fusion protein composed of the
ATF2 transactivation domain and the GAL4 DNA–bind-
ing domain, and either MKK6 (Glu) or pCEP. Transfec-
tion with MKK6 (Glu) or treatment pCEP-transfected
cells with PE enhanced ATF2-mediated luciferase produc-
tion (Fig. 5 C). Moreover, SB 203580 served as a potent in-
hibitor of MKK6 (Glu)–activated ATF2, consistent with a
major requirement for p38. Interestingly, PE-activated
ATF2 was only partially blocked by SB 203580 (Fig. 5 C),
as was PE-activated BNP transcription (Fig. 5 B), suggest-
ing that the ability of this agonist to activate cardiac gene
expression is partly dependent on p38, or a very similar ki-
nase.
The SB 203580 compound also had potent inhibitory ef-
fects on myocardial cell size and sarcomeric organization
induced by PE or MKK6 (Glu) (Fig. 7). PE- or MKK6
(Glu)–mediated sarcomeric organization and increases in
cell size were reduced by .90% by SB 203580 (Fig. 8).
These results are consistent with a central role for a p38-
like pathway in myocardial cell growth conferred by PE or
by MKK6 (Glu).
Recent studies have established that the transcription
factor, MEF2C, serves as a specific substrate for p38, such
that phosphorylation on serine 387 confers MEF2C-medi-
ated transcriptional activation in RAW 264.1 cells (Han et
al., 1997). Accordingly, the abilities of PE or MKK6 (Glu)
to activate MEF2C-dependent transcription in cardiac myo-
cytes were tested. Myocardial cells were cotransfected
with a reporter plasmid possessing GAL4 DNA–binding
sites cloned upstream of luciferase and a construct encod-
ing a fusion protein comprised of the MEF2C transactiva-
tion domain and the GAL4 DNA–binding domain. Using
this system, the activation of MEF2C after phosphoryla-
tion on serine 387 can be studied in the cardiac myocytes
without interference from any endogenous MEF2 family
members. Treatment with PE or transfection with MKK6
(Glu)–enhanced MEF2C-mediated luciferase production
(Fig. 9, MEF2C/Gal4). When cells were transfected with
an altered MEF2C/Gal4 chimera, in which serine 387 was
mutated to alanine, neither PE nor MKK6 (Glu) con-
ferred luciferase induction (Fig. 9, MEF2C-S/Gal4). These
results indicate that like MKK6 (Glu), PE can activate
MEF2C in cardiac myocytes, an event that requires phos-
phorylation at serine 387 by p38. This result further sup-
ports the notion that in part, PE enhances myocardial cell
growth, sarcomeric organization, and the related gene ex-
pression through a pathway involving p38 or a very similar
kinase.
Discussion
Under certain conditions, cardiac myocytes undergo non-
mitotic, hypertrophic growth that is typified by dramatic
increases in cell size, high degrees of sarcomeric organiza-
tion, and enhanced expression of certain cardiac-specific
genes. Several results from this study indicate that MKK6-
activated p38 is sufficient to confer the three main features
of this unique hypertrophic growth program. First, MKK6
(Glu), which amongst the MAPKs induces only p38 (Fig. 1
and Raingeaud et al., 1996), conferred sarcomeric organi-
zation, increased cell size, and increased cardiac gene ex-
pression in a manner similar to the well-characterized a1-
adrenergic receptor agonist, PE. Second, when induced by
MKK6, all three features of the growth program could be
blocked by the p38-specific inhibitor, SB 203580. Interest-
ingly, PE-enhanced sarcomeric organization, cell size, and,
to some extent, cardiac gene induction were also blocked
by SB 203580, indicating that the p38 pathway probably
plays an important role in a1-adrenergic receptor signaling
in myocardial cells. However, since the effects of PE on
BNP transcription and ATF2-enhanced transcription were
only partially blocked by SB 203580, it appears that while
p38 may be central to some features of the hypertrophic
response, it may play only a partial role in mediating other
aspects of the growth program.
To our knowledge, this is the first report to document
that the activation of the p38/MAPK pathway can mimic
Figure 6. Effects of PE on the activities of p38, JNK, and ERK in
myocardial cells. Myocardial cells were treated for 30 min with or
without PE (10 mM) 1 propranolol (1 mM) and then extracted
and subjected to SDS-PAGE followed by Western analyses using
antibodies (New England Biolabs, Inc., Beverly, MA) that detect
p38, JNK, or ERK only when activated by dual phosphorylation
on Thr180 and Tyr182 (following the manufacturer’s protocols).
Developed blots were then analyzed using a Molecular Dynamics
PhosphorImager. Each bar represents the mean blot intensity of
three identically treated cultures 6 SE.Zechner et al. p38/MAPK as a Mediator of Myocardial Cell Growth 123
the morphological changes and gene inductive effects of
growth factor treatment in any cell type. Thus, while p38/
MAPK is known as being a stress-activated kinase, it can
apparently contribute to cell growth in a manner that may
represent a compensatory response to stress. Although
such a role for p38 contrasts with earlier findings that p38
induces apoptosis (Xia et al., 1995), it is consistent with re-
cent studies indicating that this stress kinase can promote
survival in certain cell types (Juo et al., 1997); in this re-
spect, p38 appears to function in a cell-specific manner.
The mechanism by which MKK6-mediated p38 activa-
tion could lead to myocardial cell hypertrophic growth re-
mains to be elucidated; however, recent work has revealed
several downstream p38 targets that could be involved.
For example, p38 phosphorylates and activates several
transcription factors, such as ATF2 and Elk-1 (Gupta et
Figure 7. Fluorescent micro-
scopic analyses of the effects
of SB 203580 on size and sar-
comeric organization in myo-
cardial cells. Myocardial cells
were cotransfected with MKK6
(Glu) or an empty vector
control (pCEP and pCEP 1
PE) and CMV–b-galactosi-
dase and then plated on glass
slides, as described in the leg-
end for Fig. 3. After mainte-
nance for 48 h in serum-free
control medium with or with-
out SB 203580 (20 mM) or
DMSO (vehicle control) and
with or without PE (10 mM)
1 propranolol (1 mM), as
shown, cultures were fixed in
paraformaldehyde and im-
munostained for b-galactosi-
dase expression (Gal) (A–
F), and the same cultures
were stained for actin with
BODIPY-phalloidin (Phall)
(A9–F9). Bar, 50 mm.The Journal of Cell Biology, Volume 139, 1997 124
al., 1995; Livingstone et al., 1995; Raingeaud et al., 1995,
1996), which could augment the expression of cardiac-spe-
cific genes induced during hypertrophy. Many of these in-
ducible genes are known to possess relevant cis-acting se-
quences, including serum response elements, cAMP response
elements, AP-1 sites, and NF-kB sites. Most recently, it
has been demonstrated that the muscle cell–enriched tran-
scription factor, MEF2C, a MADS box protein known to
bind to A/T-rich regions of muscle-specific genes and
known to be required for proper growth and development
of cardiac muscle (Edmondson et al., 1994; Olson and
Srivastava, 1996), serves as a substrate for p38 but not
ERK or JNK (Han et al., 1997). In that report, the p38-
specific phosphorylation was shown to lead to the activa-
tion of MEF2C as a transcription factor. Both the rat ANP
and BNP 59-flanking regions, as well as regulatory regions
of other genes induced during the hypertrophic growth
program (e.g., a-skeletal actin and b-myosin heavy chain
genes), contain A/T-rich regions that are required for tran-
scriptional induction and could bind MEF2C or related
proteins (MacLellan et al., 1994; Thuerauf et al., 1994;
Karns et al., 1995; Sprenkle et al., 1995). Thus, it is possible
that p38 could phosphorylate and activate transcription
Figure 8. Morphometric analyses of the effects of SB 203580 on
size and sarcomeric organization in myocardial cells. (A) Photo-
graphic images of b-galactosidase–positive myocardial cells trans-
fected and treated as described in the legend to Fig. 3 were digi-
tized, and the areas were determined as described in the legend
to Fig. 4 A. Shown are the mean area values for each treatment 6
SE (n 5 3 cultures). The SB 203580 vehicle, DMSO, was included
in all controls and had a slight inhibitory effect itself on the ability
of PE and the test constructs to increase cell area. (B) The myo-
filament structure was evaluated using BODIPY-phalloidin to
stain actin, as described in the legend to Fig. 4 B. Shown are the
mean area values for each treatment 6 SE (n 5 3 cultures).
Figure 9. Effects of PE or MKK6 (Glu) on MEF2C-dependent
luciferase production in myocardial cells. Myocardial cells were
transfected with pG5E1bLuc and either Gal4 (codes for Gal4
DNA–binding domain only), MEF2C/Gal4 (codes for MEF2C
fused to the Gal4 DNA–binding domain), or MEF2C-S/Gal4
(codes for mutant [Ser to Ala 387] MEF2C fused to the Gal4
DNA–binding domain). All cells were also transfected with
CMV–b-galactosidase for normalization purposes. (A) Cultures
were maintained with or without PE (10 mM) 1 propranolol (1
mM), as shown, and then extracted and assayed for luciferase and
b-galactosidase reporter activities, as described in Materials and
Methods. (B) Cultures were also transfected with the control vec-
tor, pCEP, or with the test construct, MKK6 (Glul), maintained
in control media for 24 h, and then extracted and assayed for lu-
ciferase and b-galactosidase reporter activities, as described in
Materials and Methods. Luciferase enzyme units were normal-
ized to b-galactosidase, and the values obtained with each treat-
ment were normalized to MEF2C/Gal 4 1 PE (A) or MEF2C/
Gal 4 1 MKK6 (Glu) (B). Values are means 6 SE, n 5 3 cultures.Zechner et al. p38/MAPK as a Mediator of Myocardial Cell Growth 125
factors that augment the expression of genes that partici-
pate in the cardiac growth program.
Alternatively, p38 may activate other downstream ki-
nases that serve as the final steps in the signaling program.
For example, it is well known that p38 can phosphorylate
and activate MAP kinase–activated protein kinases (MAP-
KAPs)-1, -2, and -3 (MAPKAP-3 a.k.a. 3pK) (Stokoe et al.,
1992a; Young et al., 1993; Rouse et al., 1994; English et al.,
1995; Ludwig et al., 1996; McLaughlin et al., 1996; Sitha-
nandam et al., 1996; Tan et al., 1996). In response to p38
activation by growth factors, MAPKAPs have been shown
to phosphorylate and activate selected transcription fac-
tors, such as CREB and ATF-1, usually at protein kinase
A/CaMK consensus sequences (Tan et al., 1996). Thus, it
is possible that via the MAPKAPs, myocardial cell p38
stimulation could culminate with the activation of tran-
scription factors often thought of as being downstream of
non-MAPKs, e.g., protein kinase A or CaMK.
In addition to altering the function of transcription fac-
tors, p38-mediated MAPKAP/3pK activation could modu-
late other pathways that might favor cell survival, and in
cardiac myocytes, these pathways could contribute to the
development of myocardial cell-specific features, such as
myofilament organization. For example, MAPKAP-2 has
been shown to be activated during ischemic precondition-
ing of isolated rat hearts (Bogoyevitch et al., 1996; Maulik
et al., 1996). Such preconditioning is known to serve as a
myocardial stress adaptation, resulting in enhanced pro-
tection from ischemia-induced myocardial cell death (Murry
et al., 1986; Parratt, 1994; Cumming et al., 1996; Gottlieb
et al., 1996). In part, it is believed that this cardioprotec-
tion is derived from the induction and activation of heat-
shock proteins (hsp’s) 27 and 70 (Marber et al., 1993;
Mestril et al., 1994; Parratt, 1994), both of which are known
to protect cells from apoptosis (Mehlen et al., 1996; Samali
and Cotter, 1996; Sharma et al., 1996). Interestingly,
MAPKAP-2 and -3 have been shown to phosphorylate hsp
27, a modification known to enhance its protective proper-
ties (Ahlers et al., 1994; Huot et al., 1995). Moreover, after
phosphorylation induced by either heat-shock or mitogen
stimulation, hsp 27 has been shown to bind to and stabilize
actin filaments in mouse fibroblasts (Lavoie et al., 1993).
Such hsp 27–mediated filament stabilization in cardiac myo-
cytes could be a major contributor to the striking sarco-
meric organization observed upon MKK6-mediated p38
activation. Intracellular signaling pathways leading to hsp
activation and/or phosphorylation in cardiac myocytes
could conceivably extend back to a1-adrenergic receptors.
Indeed, adrenergic receptor stimulation has been shown to
activate hsp’s in a variety of cell types; most notable is the
finding that a1-adrenergic agonists activate hsp 70 in rat
aortic cells (Chin et al., 1996) and in rat cardiac cells
(Meng et al., 1996).
In summary, our results demonstrate a role for MKK6
and p38 in myocardial cell hypertrophic growth and gene
expression. This is consistent with the view that the hyper-
trophic growth program represents a compensatory re-
sponse of the myocardium to stress. In a physiological con-
text, the mediators of the hypertrophic response are often
hemodynamic stresses, such as increases in blood pressure
or volume. Accordingly, increases in myocardial cell size
and contractile function afforded by such growth could be
viewed as cellular adaptations designed to counteract a
physiological stress. Indeed, induction of the cardiac natri-
uretic peptide genes, which encode hormones that de-
crease blood pressure and volume, represent an endocrine
compensatory response by the myocardium. The findings
that the p38 pathway can mediate all three primary fea-
tures of the myocardial cell growth program represent a
major advancement in our understanding of the signals
that regulate this important induction process. Future
studies aimed at determining how other signaling path-
ways, perhaps even the other MAPK pathways, comple-
ment the p38 pathway and how p38 itself contributes to
myocyte growth, sarcomeric organization, and cardiac
gene induction, should reveal new roles for this interesting
stress-kinase pathway in the heart.
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